Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.451 |
|---|---|
| High | 0.451 |
| Low | 0.3679 |
| Bid | 0.40 |
| Offer | 0.4041 |
| Previous close | 0.4526 |
| Average volume | 391.04k |
|---|---|
| Shares outstanding | 18.65m |
| Free float | 16.08m |
| P/E (TTM) | -- |
| Market cap | 8.44m USD |
| EPS (TTM) | -0.6345 USD |
Data delayed at least 15 minutes, as of Feb 17 2026 21:00 GMT.
More ▼
- Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care
- Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
- Nexalin Technology Receives Nasdaq Listing Status Notification
- Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD
- Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
- Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
- Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity
- Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
- Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
- Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
More ▼
